Skip to main content
  • Original article
  • Open access
  • Published:

Prognostic value of serum autotaxin in liver cirrhosis and prediction of hepatocellular carcinoma

Abstract

Background

Autotaxin is a lysophospholipase D related to liver fibrosis; its clinical role in liver cirrhosis is still unknown or limited. In this study we investigate the relation of autotaxin serum levels and prognosis of liver disease and/or prediction of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV) patients.

Patients and methods

This observational, prospective case–control study included 180 participants, 60 patients with HCV-related liver cirrhosis, 60 HCV noncirrhotic patients, and 60 healthy controls. They were enrolled from inpatients and clinics of a tertiary-care hospital. Baseline characteristics, serum autotaxin, Child–Turcotte–Pugh and model of end-stage liver disease scores were determined. Abdominal ultrasound and upper gastrointestinal endoscopy were done at the beginning of the study. Cirrhotic patients were prospectively followed up for 6 months.

Results

Patients with liver cirrhosis had the highest level of autotaxin (106±24 μg/ml) compared with noncirrhotic HCV patients (81.9±21 μg/ml) and healthy controls (42.5±11 μg/ml) using one-way analysis of variance test (P=0.000). Spearman’s correlation analysis showed no significant correlation between autotaxin and Child–Turcotte–Pugh score (r=0.02; P<0.70), and model of end-stage liver disease score (r=0.15; P<0.41). At 6 months of follow-up, patients who developed HCC or encephalopathy had significantly higher baseline autotaxin level (141±55 μg/ml; P=0.02, 117±56.6 μg/ml; P=0.000), respectively, than patients who did not (102±34, 90.7±40 μg/ml). Cutoff values of autotaxin for the prediction of HCC and encephalopathy were 95 and 92μg/ml, respectively, with 91 and 92% sensitivity.

Conclusion

Autotaxin is a sensitive predictor for the development of HCC and encephalopathy in HCV-related cirrhotic patients. However, it was not related to disease severity.

References

  1. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014; 383:1749–1761.

    PubMed  Google Scholar 

  2. Poca M, Puente A, Graupera I, Villanueva C. Prognostic markers in patients with cirrhosis and portal hypertension who have not bled. Dis Markers 2011; 31:147–154.

    Article  PubMed  PubMed Central  Google Scholar 

  3. de Franchis R, Dell’Era A. Invasive and noninvasive methods to diagnose portal hypertension and esophageal varices. Clin Liver Dis 2014; 18:293–302.

    Article  PubMed  Google Scholar 

  4. Watterson K, Lanning D, Diegelmann R, Spiegel S. Regulation of fibroblast functions by lysophospholipid mediators: potential roles in wound healing. Wound Repair Regen 2007; 15:607–616.

    Article  PubMed  Google Scholar 

  5. Georas S. Lysophosphatidic acid and autotaxin: emerging roles in innate and adaptive immunity. Immunol Res 2009; 45:229–238.

    Article  CAS  PubMed  Google Scholar 

  6. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007; 117:524–529.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Ikeda H, Watanabe N, Nakamura K, Kume Y, Nakai Y, Fujishiro M, et al. Significance of serum autotaxin activity in gastrointestinal disease. Rinsho Byori 2009; 57:445–449.

    CAS  PubMed  Google Scholar 

  8. Kondo M, Ishizawa T, Enooku K, et al. Increased serum autotaxin levels in hepatocellular carcinoma patients were caused by background liver fibrosis but not by carcinoma. Clin Chim Acta 2014; 433:128–134.

    Article  CAS  PubMed  Google Scholar 

  9. Pleli T, Martin D, Kronenberger B, Brunner F, Köberle V, Grammatikos G, et al. Serum autotaxin is a parameter for the severity of liver cirrhosis and overall survival in patients with liver cirrhosis-a prospective cohort study. PLoS One 2014; 9:e103532.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Yamaoka K, Nouchi T, Marumo F, Satoc C. Alpha-smooth-muscle actin expression in normal and fibrotic human livers. Dig Dis Sci 1993; 38:1473–1479.

    Article  CAS  PubMed  Google Scholar 

  11. Ikeda H, Nagashima K, Yanase M, Tomiya T, Arai M, Inoue Y, et al. Involvement of Rho/Rho kinase pathway in regulation of apoptosis in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2003; 285: G880–G886.

    Article  CAS  PubMed  Google Scholar 

  12. Watanabe N, Ikeda H, Nakamura K, et al. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol 2007; 41:616–623.

    Article  CAS  PubMed  Google Scholar 

  13. Nakagawa H, Ikeda H, Nakamura K, et al. Autotaxin as a novel serum marker of liver fibrosis. Clin Chim Acta 2011; 412:1201–1206.

    Article  CAS  PubMed  Google Scholar 

  14. Bain G, Shannon KE, Huang F, et al. Selective inhibition of autotaxin is efficacious in mouse models of liver fibrosis. J Pharmacol Exp Ther 2017; 360:1–13.

    Article  CAS  PubMed  Google Scholar 

  15. Yanase M, Ikeda H, Ogata I, et al. Functional diversity between Rho-kinase and MLCK-mediated cytoskeletal actions in a myofibroblast like hepatic stellate cell line. Biochem Biophys Res Commun 2003; 305:223–228.

    Article  CAS  PubMed  Google Scholar 

  16. Ikeda H, Yatomi Y, Yanase M, et al. Effects of lysophosphatidic acid on proliferation of stellate cells and hepatocytes in culture. Biochem Biophys Res Commun 1998; 248:436–440.

    Article  CAS  PubMed  Google Scholar 

  17. Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Tomiya T, et al. Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity. Life Sci 2007; 81:1009–1015.

    Article  CAS  PubMed  Google Scholar 

  18. Jansen S, Andries M, Vekemans K, Vanbilloen H, Verbruggen A, Bollen M. Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells. Cancer Lett 2009; 284:216–221.

    Article  CAS  PubMed  Google Scholar 

  19. Kostadinova L, Shive CL, Judge C, Zebrowski E, Compan A, Rife K, et al. During hepatitis c virus (HCV) infection and HCV-HIV coinfection, an elevated plasma level of autotaxin is associated with lysophosphatidic acid and markers of immune activation that normalize during interferon-free HCV therapy. J Infect Dis 2016; 214:1438–1448.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Xia Q, Deng AM, Wu SS, Zheng M. Cholera toxin inhibits human hepatocarcinoma cell proliferation in vitro via suppressing ATX/LPA axis. Acta Pharmacol Sin 2011; 32:1055–1062.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Wu JM, Xu Y, Skill NJ, Sheng H, Zhao Z, Yu M, et al. Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma. Mol Cancer 2010; 9:71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Cooper AB, Wu J, Lu D, Maluccio MA. Is autotaxin (ENPP2) the link between hepatitis C and hepatocellular cancer? J Gastrointest Surg 2008; 11:1628–1634.

    Article  Google Scholar 

  23. Auroux J, Lamarque D, Roudot-Thoraval F, Deforges L, Chaumette MT, Richardet JP, Delchier JC. Gastroduodenal ulcer and erosions are related to portal hypertensive gastropathy and recent alcohol intake in cirrhotic patients. Dig Dis Sci 2003; 48:1118–1123.

    Article  CAS  PubMed  Google Scholar 

  24. Seo W, Jeong WI. Hepatic non parenchymal cells: master regulators of alcoholics liver disease?. World J Gastroenterol 2016; 22:1348–1356.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Ciecko-Michalska I, Szczepanek M, Słowik A, Mach T. Pathogenesis of hepatic encephalopathy. Gastroenterol Res Pract 2012; 2012:642108.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nagwa Ramadan Ahmed.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ahmed, N.R., EL-Mazny, A.N., Hassan, S.A. et al. Prognostic value of serum autotaxin in liver cirrhosis and prediction of hepatocellular carcinoma. Egypt J Intern Med 31, 849–855 (2019). https://doi.org/10.4103/ejim.ejim_63_19

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_63_19

Keywords